相关实验视频

Updated: Jul 4, 2025

Visualization of Estrogen Receptors in Colons of Mice with TNBS-Induced Crohn's Disease using Immunofluorescence

Visualization of Estrogen Receptors in Colons of Mice with TNBS-Induced Crohn's Disease using Immunofluorescence

Published on: March 12, 2020

研究雌激素受体调节剂对免疫检查点分子的潜在影响

Nikita Abramenko^1,2, Fréderic Vellieux^1,2, Kateřina Veselá^1,2

¹BIOCEV, First Faculty of Medicine, Charles University, 252 50, Vestec, Czech Republic.

Scientific reports

|February 6, 2024

概括

选择性雌激素受体调节剂 (SERM) 显示出作为免疫检查点抑制剂的潜力. 某些SERM,如 Estrol和bazedoxifene,可能会阻断PD-1和CTLA-4,提供新的癌症免疫治疗途径.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
在瘤学瘤学.

背景情况:

免疫检查点,如PD-1/PD-L1和CTLA-4,是免疫反应的关键调节者.
黄和植物雌激素被认为可以调节免疫检查点路径.
选择性雌激素受体调节剂 (SERM) 是一类具有多种生物活性的化合物.

研究的目的:

调查雌激素和17个SERM作为免疫检查点蛋白 (CTLA-4,PD-L1,PD-1和CD80) 的抑制配体的潜力.
探索SERM在癌症免疫疗法免疫检查点抑制中的治疗含义.

主要方法:

用分子对接研究来评估雌激素和SERM的结合亲和力,以准免疫检查点蛋白.
对结合能量值的分析,以预测抑制潜力.

主要成果:

昆醇,奎尔丁和巴兹多克西芬表现出强大的结合能量值,这表明PD-1和CTLA-4的潜在抑制.
基基芬和氨酸,也调节EGFR和IL-6R,证明了对免疫检查点功能的潜在影响.
该研究确定了具有与PD-1和CTLA-4有希望的抑制相互作用的特定SERM.

结论:

SERM可以作为免疫检查点蛋白的抑制配体,特别是PD-1和CTLA-4.
这些发现表明,SERM通过免疫检查点抑制具有治疗潜力.
这项研究通过准SERM和免疫检查点通路之间的相互作用,为开发癌症免疫疗法开辟了新的途径.

更多相关视频

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...